Bristol Myers Squibb (BMS) is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program.

SAN DIEGO and PENNINGTON, N.J., — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”) today announced that in connection with its previously announced offering of common stock, it has entered into purchase agreements for the purchase of an aggregate 4,608,589 shares of the Company at an offering price of $3.25 per share for aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses. The offering is expected to close on or about August 19, 2020.

Sanofi has struck a deal to buy its partner Principia Biopharma for $3.7 billion in cash. The takeover will give Sanofi full ownership of a BTK inhibitor it moved into a raft of phase 3 multiple sclerosis trials earlier this year.

JW Therapeutics has filed the paperwork (PDF) for a Hong Kong IPO. The Juno Therapeutics-WuXi AppTech joint venture is seeking money to advance a cell therapy pipeline led by anti-CD19 CAR-T JWCAR029.

The artificial intelligence-powered drug designer Atomwise has raised $123 million in venture capital funding, to both scale up its platform and its partnerships with large biopharma companies, and to begin developing its own pipeline of promising molecules.

Urovant may be gearing up for its first commercial launch, but that doesn’t mean it’s taking its eye off the R&D ball. As it builds its commercial organization for its overactive bladder treatment, the company pushing the same drug through the clinic in other indications, and working on a gene therapy, too.

Calliditas is spending a little over €20 million for a controlling stake in Genkyotex in the hope it can help revive its faltering attempts in primary biliary cholangitis (PBC).

Danish drugmaker Novo Nordisk is opening up its bleeding disorder trials five months after they were stopped.

Just last week, MicuRx nabbed nearly $43 million in venture funding to expand its antibiotics pipeline and gear up for its first launch in China. Now, the Sino-American biotech is topping that up with $7.78 million from a nonprofit focused on antimicrobial resistance to push another asset into human trials.

Biotech, digital health and medtech incubator Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital (PHC).